September 23, 2014 5:58 AM ET

Healthcare Equipment and Supplies

Company Overview of ArraVasc Limited

Company Overview

ArraVasc Limited designs, manufactures, and markets devices for interventional clinicians. The company develops catheters; and novel access technologies for the treatment of coronary artery disease. It focuses on peripheral vascular diseases. The company supplies its products to strategic OEM partners through distributors. ArraVasc Limited was formerly known as Cappella Medical Devices Limited and changed its name to ArraVasc Limited in May 2014. The company was incorporated in 2005 and is based in Galway, Ireland. Cappella Medical Devices Limited operates as a subsidiary of Cappella Inc.

Unit 2

Ballybrit Business Park



Founded in 2005


353 9 175 8939


353 9 175 8930

Key Executives for ArraVasc Limited

Chief Executive Officer and Director
Chief Financial Officer and Director
Head of Operations
Vice President of Commercial Operations
Compensation as of Fiscal Year 2014.

ArraVasc Limited Key Developments

Cappella Medical Devices Limited Announces Long Term Follow-Up Results for Sideguard(R) Technology

Cappella Medical Devices Limited announced the multicenter long term follow up results for its innovative Sideguard(R) coronary sidebranch stent. Long term follow up data on the Sideguard stent was obtained from 399 patients from the United Kingdom, Germany, and Italy. The MACE rate was: 3.7% (30 day F/U), 7.1% (6 mo F/U) and 10.2% (1 year F/U) comparing favourably with existing standard practice. This data represents the multicenter clinical experience to date with the Sideguard technology. The Sideguard was developed to protect the ostium of the sidebranch offering interventional cardiologists a dynamic, effective, and easy-to-use solution in the treatment of bifurcation disease. Results from this multicenter experience have confirmed that preservation of the sidebranch of diseased coronary arteries by protecting the ostium has clear long term benefits when compared to existing standard practice of provisional and two-stent procedures. Up to 30% of all PCI patients have bifurcation disease yet there has not been one proven dedicated treatment solution. Treating these patients has always been a challenge for physicians due to the complex anatomy of the coronary sidebranch. Gary Brogan, VP of Regulatory and Clinical Affairs at Cappella, stated, "Up until now, physicians have been forced to treat the bifurcation with either two stents that weren't intended for this use, or one main vessel stent that has limitations in terms of ostial protection and sidebranch preservation. The provisional and two-stent techniques used all involve manipulating the straight DES stent struts in an attempt to provide clear access into the sidebranch. Data is now being presented documenting the negative flow dynamic and shear stress issues of floating stent struts. This long term follow up data validates the unique advantages of the Cappella Sideguard technology even when compared to existing DES treatment options.

Similar Private Companies By Industry

Company Name Region
Biosensia Ltd. Europe
Cardio ApomiX Limited Europe
Cappella Inc. Europe
Innovation Zed Ltd. Europe
Vysera Biomedical Limited Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ArraVasc Limited, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at